Unknown

Dataset Information

0

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.


ABSTRACT: Coronary heart disease (CHD) remains the leading cause of death in Germany despite statin use to reduce low-density lipoprotein cholesterol (LDL-C) levels; improving lipids beyond LDL-C may further reduce cardiovascular risk. A fixed-dose combination of extended-release niacin (ERN) with laropiprant (LRPT) provides comprehensive lipid management. We adapted a decision-analytic model to evaluate the economic value (incremental cost-effectiveness ratio [ICER] in terms of costs per life-years gained [LYG]) of ERN/LRPT 2 g over a lifetime in secondary prevention patients in a German setting. Two scenarios were modelled: (1) ERN/LRPT 2 g added to simvastatin 40 mg in patients not at LDL-C goal with simvastatin 40 mg; (2) adding ERN/LRPT 2 g compared with titration to simvastatin 40 mg in patients not at LDL-C goal with simvastatin 20 mg. In both scenarios, adding ERN/LRPT was cost-effective relative to simvastatin monotherapy at a commonly accepted threshold of €30,000 per LYG; ICERs for ERN/LRPT were €13,331 per LYG in scenario 1 and €17,684 per LYG in scenario 2. Subgroup analyses showed that ERN/LRPT was cost-effective in patients with or without diabetes, patients aged ? 65 or >65 years and patients with low baseline high-density lipoprotein cholesterol levels; ICERs ranged from €10,342 to €15,579 in scenario 1, and from €14,081 to €20,462 in scenario 2. In conclusion, comprehensive lipid management with ERN/LRPT 2 g is cost-effective in secondary prevention patients in Germany who have not achieved LDL-C goal with simvastatin monotherapy.

SUBMITTER: Michailov GV 

PROVIDER: S-EPMC3343242 | BioStudies | 2012-01-01T00:00:00Z

SECONDARY ACCESSION(S): NCT00461630

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4019613 | BioStudies
1000-01-01 | S-EPMC3640201 | BioStudies
2016-01-01 | S-EPMC4942972 | BioStudies
2016-01-01 | S-EPMC4801501 | BioStudies
2010-01-01 | S-EPMC2887787 | BioStudies
2019-01-01 | S-EPMC6611514 | BioStudies
2013-01-01 | S-EPMC4886540 | BioStudies
2015-01-01 | S-EPMC4568069 | BioStudies
2018-01-01 | S-EPMC5931743 | BioStudies
2016-01-01 | S-EPMC4914402 | BioStudies